PneumoNP presentation Nanotherapeutics to treat antibiotic resistant Gram- negative respiratory...
8
Logo Speaker PneumoNP presentation Nanotherapeutics to treat antibiotic resistant Gram-negative respiratory infections
-
Upload
junior-holt -
Category
Documents
-
view
215 -
download
0
Transcript of PneumoNP presentation Nanotherapeutics to treat antibiotic resistant Gram- negative respiratory...
Logo Speaker
PneumoNP presentation
Nanotherapeutics to treat antibiotic resistant Gram-negative respiratory infections
PneumoNP presentation
Introduction
A European research project
Nanotherapeutics to treat antibiotic resistant Gram-negative pneumonia infections
•Funded under the Seventh Framework Programme•Collaborative project•More than 5.5M€•2014-2017
Logo Speaker
•Klebsiella pneumoniae as proof of concept
Objectives
Project expected outcomes:•a new inhablable drug composed of a nanotherapeutic system: an active antibacterial and a nanocarrier;
•a new aerosol technology specifically developed for the nanotherapeutic system;
•an innovative efficiency-efficacy test to follow-up the treatment;
•And a new diagnostic kit for the rapid and multiplex identification of bacteria causing respiratory infections.
Logo SpeakerPneumoNP presentation
Work plan
Logo SpeakerPneumoNP presentation
Partners
Logo SpeakerPneumoNP presentation
Research institutes
UniversitiesSMEs
Entreprise
Clinicians
11 partners
6 countries: Spain, Danemark, Germany, Italy, France, The Netherlands
Each with a distinctive role
PneumoNP towards OI model
Logo SpeakerPneumoNP presentation
PneumoNP position in the nanomedicine value chain strenghtened by:
1. Good cooperation between all stakeholders
2. Integration of regulatory issues from the early stages of development
3. Awareness of scalability and GMP production
Economic impact
Nanomedicine is a key component for pharma companies willing to maintain their competitiveness today.
Expected market size (M€) 2015 2020 2025
Non-invasive delivery of protein nanomedicines 0 10,000 ± 5,000 20,000 ± 10,000
Non-invasive delivery of nucleic acid based nanomedicines
0 5,000 ± 2,000 10,000 ± 5,000
PneumoNP presentation
$63.8 billion
2010
$130.9 billion
2016 Expected growth of the
nanomedicine market if research is correctly oriented and pushed
forward
Urgent need of MDR antibacterials and lack of new agents reaching the market..
Questions ?
Find us
Logo SpeakerPneumoNP presentation
You can find out more about the PneumoNP project on our website. Follow us on Twitter to get the latest news, or on LinkedIn to share your expertise with us!
@PneumoNP
PneumoNPwww.pneumonp.eu
?
